Senescence dysregulates of inflammation-resolution programs in atherosclerosis
动脉粥样硬化炎症消退程序的衰老失调
基本信息
- 批准号:10427260
- 负责人:
- 金额:$ 61.78万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-15 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:AcetylationAcuteAreaArterial Fatty StreakAtherosclerosisBlocking AntibodiesCancer PatientCardiovascular DiseasesCause of DeathCell AgingCell Cycle ArrestCell physiologyCellsChronicDataDietDinoprostoneEatingEnzymesEquilibriumEtiologyEventExhibitsGlycolysisHumanImpairmentIn VitroIndustrializationInflammationInflammatoryInflammatory ResponseKnowledgeLesionLeukotrienesLinkLipoxinsMediatingMediator of activation proteinModelingMusMyelogenousMyeloid CellsNecrosisPTGS2 genePhenotypeProcessProductionProstaglandinsRadiationRegulationResearchResolutionSeriesSignal PathwaySignal TransductionSurfaceTestingWorkbasecardiovascular disorder riskdriving forcehypercholesterolemiaimprovedin vivoinsightmouse modelnovelpreventprogramspublic health prioritiesrestorationsenescencetissue injurytissue repairtreatment strategy
项目摘要
Atherosclerotic cardiovascular disease (CVD) is the leading cause of death in the industrialized world. Failed
resolution of a chronic inflammatory response is an important driving force in the progression of
atherosclerosis. Resolution is mediated by the critical balance between specialized pro-resolving mediators
(SPMs) such as lipoxins and resolvins and pro-inflammatory factors like leukotrienes (LTs) and prostaglandins
(PGs). Previous work from our lab and others suggest that SPMs are defectively synthesized in plaques and
that restoration of SPMs prevents atherosclerosis progression in mice. Gaps remain in our understanding as to
a) what cellular processes derange the synthesis of SPMs in
protective actions of SPMs in atherosclerosis. Therefore, the
plaques and b) mechanisms associated with the
overall objective of this proposal is to understand
new mechanisms of dysregulated resolution in atherosclerosis and to harness new SPM signaling pathways
towards a novel treatment strategy. Cellular senescence is an irreversible cell cycle arrest that leads to a highly
pro-inflammatory phenotype called the senescence-associated secretory phenotype (SASP). Prominent
features of senescent cells (SCs) include elevated levels of COX2 and PGs and heightened glycolysis. SCs
recently emerged as a driver of plaque necrosis but mechanisms are poorly understood. Our new work
suggests that senescence impairs endogenous resolution programs and that key SPMs can limit the SASP.
We proposed a series of studies to identify the mechanisms associated with senescence and impaired
resolution (Aim I), the link between myeloid senescent cells and SPM formation in plaques (Aim II) and
mechanisms underlying how hypercholesterolemia impacts senescence and SPM synthesis (Aim III). The link
between dysregulated resolution programs and senescence is a completely new and unexplored area of
research that may reveal new treatment strategies for atherosclerosis that are complementary to those that
currently exist.
动脉粥样硬化性心血管疾病(CVD)是工业化国家的主要死亡原因。失败
慢性炎症反应的消退是慢性炎症进展的重要驱动力。
动脉粥样硬化解决是由专业的亲解决调解员之间的关键平衡调解
(SPM)如脂氧素和消退素以及促炎因子如白三烯(LT)和白藜芦醇
(PG)。我们实验室和其他人以前的工作表明,SPM在斑块中的合成是有缺陷的,
SPMs的恢复阻止了小鼠动脉粥样硬化的进展。我们对以下问题的理解仍然存在差距:
a)什么细胞过程扰乱了SPM的合成,
SPM在动脉粥样硬化中的保护作用。因此
斑块和B)与
本提案的总体目标是了解
动脉粥样硬化中失调消退的新机制和利用新的SPM信号通路
一种新的治疗策略。细胞衰老是一种不可逆的细胞周期停滞,导致细胞高度衰老。
促炎表型称为衰老相关分泌表型(SASP)。突出
衰老细胞(SC)的特征包括升高的COX 2和PG水平以及增强的糖酵解。SCS
最近作为斑块坏死的驱动因素出现,但机制知之甚少。我们的新工作
表明衰老损害内源性解决方案和关键SPM可以限制SASP。
我们提出了一系列的研究,以确定与衰老和受损的机制,
解决(目的I),髓样衰老细胞和斑块中SPM形成之间的联系(目的II),
高胆固醇血症如何影响衰老和SPM合成的潜在机制(Aim III)。链路
失调的解决方案和衰老之间的关系是一个全新的和未探索的领域,
这项研究可能揭示动脉粥样硬化的新治疗策略,
目前存在。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Gabrielle Fredman其他文献
Gabrielle Fredman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Gabrielle Fredman', 18)}}的其他基金
Inflammation-resolution impairments in aging and atherosclerosis
衰老和动脉粥样硬化中的炎症消退障碍
- 批准号:
10724859 - 财政年份:2023
- 资助金额:
$ 61.78万 - 项目类别:
Senescence dysregulates of inflammation-resolution programs in atherosclerosis
动脉粥样硬化炎症消退程序的衰老失调
- 批准号:
10025692 - 财政年份:2020
- 资助金额:
$ 61.78万 - 项目类别:
Senescence dysregulates of inflammation-resolution programs in atherosclerosis
动脉粥样硬化炎症消退程序的衰老失调
- 批准号:
10333044 - 财政年份:2020
- 资助金额:
$ 61.78万 - 项目类别:
Senescence dysregulates of inflammation-resolution programs in atherosclerosis
动脉粥样硬化炎症消退程序的衰老失调
- 批准号:
10631070 - 财政年份:2020
- 资助金额:
$ 61.78万 - 项目类别:
Senescence dysregulates of inflammation-resolution programs in atherosclerosis
动脉粥样硬化炎症消退程序的衰老失调
- 批准号:
10214691 - 财政年份:2020
- 资助金额:
$ 61.78万 - 项目类别:
Senescence dysregulates of inflammation-resolution programs in atherosclerosis
动脉粥样硬化炎症消退程序的衰老失调
- 批准号:
10848738 - 财政年份:2020
- 资助金额:
$ 61.78万 - 项目类别:
Senescence dysregulates of inflammation-resolution programs in atherosclerosis
动脉粥样硬化炎症消退程序的衰老失调
- 批准号:
10629852 - 财政年份:2020
- 资助金额:
$ 61.78万 - 项目类别:
Necroptosis Impairs Inflammation-Resolution Programs in Atherosclerosis
坏死性凋亡损害动脉粥样硬化的炎症消退程序
- 批准号:
9496529 - 财政年份:2018
- 资助金额:
$ 61.78万 - 项目类别:
Necroptosis Impairs Inflammation-Resolution Programs in Atherosclerosis
坏死性凋亡损害动脉粥样硬化的炎症消退程序
- 批准号:
10349539 - 财政年份:2018
- 资助金额:
$ 61.78万 - 项目类别:
Specialized pro-resolving mediators in atherosclerosis
动脉粥样硬化的专门促解决介质
- 批准号:
8566813 - 财政年份:2013
- 资助金额:
$ 61.78万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 61.78万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 61.78万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 61.78万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 61.78万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 61.78万 - 项目类别:
Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 61.78万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 61.78万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 61.78万 - 项目类别:
Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 61.78万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 61.78万 - 项目类别:
Operating Grants